Plasma level of soluble receptor for advanced glycation end-products and aquaporin 5 in preterm infants with acute respiratory distress syndrome.
The aim of this study was to determine the plasma level of soluble receptors for advanced glycation end-products (sRAGE) and aquaporin 5 (AQP5) in preterm infants with acute respiratory distress syndrome (RDS). Forty-three preterm infants diagnosed with RDS were the experimental group. Ten apparently healthy preterm neonate infants were as normal controls. The experimental group was further divided into three subgroups based on PaO2/FiO2 (P/F): the mild group (200<P/F<300), the moderate group (100<P/F≤200) and the severe group (P/F≤100). Collected the plasma of all 53 newborns at 24, 48 and 72 hours after birth, detected the plasma level of sRAGE and AQP5 by enzyme linked immunosorbent assay. The plasma levels of sRAGE and AQP5 of the control group were significantly lower than that of experimental group at three time points (all P<0.05). The severity of RDS in preterm infants seemed to be associated with the plasma level of sRAGE and AQP5: the more severe the disease, the higher the plasma level of sRAGE and AQP5. The plasma level of sRAGE and AQP5 might be associated with the severity of RDS in preterm infants.